RSS

marketing authorisation application (MAA)

The marketing authorisation application (MAA) for cemiplimab as a potential treatment for advanced cutaneous squamous cell carcinoma (CSCC) has been accepted for review by the European Medicines Agency (EMA). more

News

Shire has announced that the European Medicines Agency (EMA) has validated its marketing authorisation application (MAA) for lanadelumab (SHP643) for investigational Hereditary Angioedema (HAE) treatment. more

News

The European Medicines Agency (EMA) has accepted the marketing authorisation application (MAA) of a biosimilar version of Neulasta (pegfilgrastim) to treat chemotherapy-induced neutropenia from Cinfa Biotech. more

News

Global biotechnology company, Shire, has submitted a marketing authorisation application (MAA) for its dry eye treatment, liftegrast, which, if approved, would represent the first and only LFA-1 antagonist drug to treat the disease in Europe. more

News

Global research and development-based pharmaceutical company, Eisai, has submitted a marketing authorization application to the European Medicines Agency (EMA) for its first-line hepatocellular carcinoma treatment, lenvatinib. more

News

The European Medicines Agency (EMA) has accepted for regulatory review the marketing authorisation applications for biosimilars to AbbVie’s Humira (adalimumab) and Janssen’s Remicade (infliximab) from Sandoz more

News

Biopharmaceutical company, TiGenix, has submitted responses to the marketing authorisation application for Cx601, a treatment of complex perianal fistulas in Crohn’s disease patients as a first indication. more

News

Kiadis Pharma, a clinical stage biopharmaceutical company, has submitted a marketing authorisation application (MAA) to the EMA for its lead product ATIR101 more

News

Helsinn’s anamorelin HCI has been accepted for marketing authorisation application (MAA) review by the European Medicines Agency (EMA) more

News